Related Experiment Video

Updated: May 22, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Recent clinical trials in atrial fibrillation in hypertensive patients

Athanasios J Manolis1, Manolis S Kallistratos, Leonidas E Poulimenos

  • 1Department of Cardiology, Asklepeion General Hospital, 1, Vassileos Pavlou St, Voula, Athens, 16673, Greece. ajmanol@otenet.gr

Current Hypertension Reports
|May 12, 2012
PubMed

Insights

Atrial Fibrillation (AF), a common heart rhythm disorder, increases stroke risk. Management involves antihypertensives, antiarrhythmics, and risk stratification scores like CHADS2 and HAS-BLED for optimal antithrombotic therapy.

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Pharmacology

Background:

  • Atrial Fibrillation (AF) is the most prevalent cardiac arrhythmia.
  • Hypertension (HTN) is the most common cardiovascular disorder.
  • AF significantly elevates stroke risk, both symptomatic and silent.

Purpose of the Study:

  • To review the role of antihypertensive regimens in AF prevention.
  • To discuss the efficacy and safety of novel antiarrhythmic drugs.
  • To highlight stroke and bleeding risk assessment in AF management.

Main Methods:

  • Literature review of recent publications on AF management.
  • Analysis of data on antihypertensive and antiarrhythmic therapies.
  • Evaluation of stroke risk stratification scores (CHADS2, HAS-BLED) and anticoagulants.

Main Results:

  • Antihypertensive treatments show promise in AF prevention.
  • Novel antiarrhythmics like dronedarone and vernakalant offer new therapeutic options.
  • Risk scores effectively guide antithrombotic therapy, balancing efficacy and hemorrhagic risk.

Conclusions:

  • Current research supports antihypertensives and novel antiarrhythmics in AF management.
  • Risk stratification tools are crucial for personalized antithrombotic strategies.
  • Emerging anticoagulants require further investigation for long-term safety and efficacy.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...